ID   F16P2_HUMAN             Reviewed;         339 AA.
AC   O00757; Q17R39; Q6FI53;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 2.
DT   22-JUL-2015, entry version 135.
DE   RecName: Full=Fructose-1,6-bisphosphatase isozyme 2;
DE            Short=FBPase 2;
DE            EC=3.1.3.11;
DE   AltName: Full=D-fructose-1,6-bisphosphate 1-phosphohydrolase 2;
DE   AltName: Full=Muscle FBPase;
GN   Name=FBP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-86.
RC   TISSUE=Skeletal muscle;
RX   PubMed=9678974; DOI=10.1016/S0378-1119(98)00181-4;
RA   Tillman H., Eschrich K.;
RT   "Isolation and characterization of an allelic cDNA for human muscle
RT   fructose-1,6-bisphosphatase.";
RL   Gene 212:295-304(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-86.
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12507293;
RA   Gizak A., Rakus D., Dzugaj A.;
RT   "Immunohistochemical localization of human fructose-1,6-bisphosphatase
RT   in subcellular structures of myocytes.";
RL   Histol. Histopathol. 18:135-142(2003).
RN   [6]
RP   ENZYME REGULATION, COFACTOR, MUTAGENESIS OF LYS-21; THR-178 AND
RP   GLN-180, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16213487; DOI=10.1016/j.febslet.2005.09.021;
RA   Rakus D., Maciaszczyk E., Wawrzycka D., Ulaszewski S., Eschrich K.,
RA   Dzugaj A.;
RT   "The origin of the high sensitivity of muscle fructose 1,6-
RT   bisphosphatase towards AMP.";
RL   FEBS Lett. 579:5577-5581(2005).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF GLU-70.
RX   PubMed=17350621; DOI=10.1016/j.febslet.2007.02.051;
RA   Zarzycki M., Maciaszczyk E., Dzugaj A.;
RT   "Glu 69 is essential for the high sensitivity of muscle fructose-1,6-
RT   bisphosphatase inhibition by calcium ions.";
RL   FEBS Lett. 581:1347-1350(2007).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, INTERACTION WITH
RP   ALDOA, AND MUTAGENESIS OF 1-MET--ASP-10.
RX   PubMed=18214967; DOI=10.1002/prot.21909;
RA   Gizak A., Maciaszczyk E., Dzugaj A., Eschrich K., Rakus D.;
RT   "Evolutionary conserved N-terminal region of human muscle fructose
RT   1,6-bisphosphatase regulates its activity and the interaction with
RT   aldolase.";
RL   Proteins 72:209-216(2008).
RN   [9]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF
RP   204-LYS--LYS-208.
RX   PubMed=19626708; DOI=10.1002/prot.22506;
RA   Gizak A., Maciaszczyk-Dziubinska E., Jurowicz M., Rakus D.;
RT   "Muscle FBPase is targeted to nucleus by its 203KKKGK207 sequence.";
RL   Proteins 77:262-267(2009).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 2-339 OF MUTANT GLN-70 IN
RP   COMPLEX WITH FRUCTOSE-6-PHOSPHATE AND AMP, AND SUBUNIT.
RX   PubMed=22120740; DOI=10.1107/S090744491104385X;
RA   Zarzycki M., Kolodziejczyk R., Maciaszczyk-Dziubinska E., Wysocki R.,
RA   Jaskolski M., Dzugaj A.;
RT   "Structure of E69Q mutant of human muscle fructose-1,6-
RT   bisphosphatase.";
RL   Acta Crystallogr. D 67:1028-1034(2011).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 2-339 OF WILD-TYPE AND
RP   MUTANT ARG-33 IN COMPLEXES WITH FRUCTOSE-6-PHOSPHATE; PHOSPHATE ION;
RP   AMP; ZINC ION AND MAGNESIUM IONS, COFACTOR, AND SUBUNIT.
RX   PubMed=24086250; DOI=10.1371/journal.pone.0071242;
RA   Shi R., Chen Z.Y., Zhu D.W., Li C., Shan Y., Xu G., Lin S.X.;
RT   "Crystal structures of human muscle fructose-1,6-bisphosphatase: novel
RT   quaternary states, enhanced AMP affinity, and allosteric signal
RT   transmission pathway.";
RL   PLoS ONE 8:E71242-E71242(2013).
CC   -!- FUNCTION: Catalyzes the hydrolysis of fructose 1,6-bisphosphate to
CC       fructose 6-phosphate in the presence of divalent cations and
CC       probably participates in glycogen synthesis from carbohydrate
CC       precursors, such as lactate. {ECO:0000269|PubMed:17350621,
CC       ECO:0000269|PubMed:18214967}.
CC   -!- CATALYTIC ACTIVITY: D-fructose 1,6-bisphosphate + H(2)O = D-
CC       fructose 6-phosphate + phosphate. {ECO:0000269|PubMed:17350621,
CC       ECO:0000269|PubMed:18214967}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:16213487,
CC         ECO:0000269|PubMed:24086250};
CC       Note=Binds 3 Mg(2+) ions per subunit.
CC       {ECO:0000269|PubMed:16213487, ECO:0000269|PubMed:24086250};
CC   -!- ENZYME REGULATION: Subject to complex allosteric regulation. The
CC       enzyme can assume an active R-state, or an inactive T-state.
CC       Intermediate conformations may exist. AMP acts as allosteric
CC       inhibitor. Fructose 2,6-bisphosphate acts as competitive
CC       inhibitor. Strongly inhibited by Ca(2+).
CC       {ECO:0000269|PubMed:16213487, ECO:0000269|PubMed:17350621,
CC       ECO:0000269|PubMed:18214967}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.3 uM for fructose 1,6-bisphosphate
CC         {ECO:0000269|PubMed:16213487, ECO:0000269|PubMed:17350621};
CC         KM=2.6 uM for fructose 1,6-bisphosphate
CC         {ECO:0000269|PubMed:16213487, ECO:0000269|PubMed:17350621};
CC         Note=The kinetic constants are determined for the recombinant
CC         enzyme expressed in E.coli.;
CC   -!- PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.
CC   -!- SUBUNIT: Homotetramer. Interacts with ALDOA; the interaction
CC       blocks inhibition by physiological concentrations of AMP and
CC       reduces inhibition by Ca(2+). Interacts with alpha-actinin and F-
CC       actin. {ECO:0000269|PubMed:18214967, ECO:0000269|PubMed:22120740,
CC       ECO:0000269|PubMed:24086250}.
CC   -!- INTERACTION:
CC       P09467:FBP1; NbExp=6; IntAct=EBI-719781, EBI-712740;
CC   -!- SUBCELLULAR LOCATION: Cell junction {ECO:0000250}. Cytoplasm.
CC       Nucleus. Cytoplasm, myofibril, sarcomere, Z line. Note=In neonatal
CC       cardiomyocytes, distributed throughout the cytosol, accumulating
CC       in the intercalated disks which occur at the Z line of
CC       cardiomyocytes and connect adjacent cells, and also located in the
CC       nucleus; dissociates from the Z line following an increase in
CC       cytosolic Ca(2+) concentration (By similarity). In muscle
CC       precursor cells, localizes predominantly to the nucleus and to a
CC       lesser extent to the cytoplasm at the proliferative phase, while
CC       mainly localizing to the cytoplasm at the differentiation phase
CC       (By similarity). Colocalizes with ALDOA and alpha-actinin on both
CC       sides of the Z line of skeletal muscle; dissociates rapidly from
CC       the Z line following an increase in cytosolic Ca(2+)
CC       concentration. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in skeletal muscle (at protein
CC       level). {ECO:0000269|PubMed:12507293}.
CC   -!- MISCELLANEOUS: Specific for the alpha-anomer of the substrate
CC       (PubMed:22120740). The Arg-33 mutant form has been shown to act on
CC       the beta-anomer (PubMed:24086250). {ECO:0000305|PubMed:22120740,
CC       ECO:0000305|PubMed:24086250}.
CC   -!- SIMILARITY: Belongs to the FBPase class 1 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y10812; CAA71772.1; -; mRNA.
DR   EMBL; CR536483; CAG38722.1; -; mRNA.
DR   EMBL; AL161728; CAH72694.1; -; Genomic_DNA.
DR   EMBL; BC113632; AAI13633.1; -; mRNA.
DR   EMBL; BC117477; AAI17478.1; -; mRNA.
DR   CCDS; CCDS6711.1; -.
DR   RefSeq; NP_003828.2; NM_003837.3.
DR   UniGene; Hs.61255; -.
DR   PDB; 3IFA; X-ray; 1.93 A; A/B/C/D=2-339.
DR   PDB; 3IFC; X-ray; 1.97 A; A/B/C/D=2-339.
DR   PDB; 4HE0; X-ray; 2.69 A; A=2-339.
DR   PDB; 4HE1; X-ray; 2.23 A; A=2-339.
DR   PDB; 4HE2; X-ray; 1.60 A; A=2-339.
DR   PDBsum; 3IFA; -.
DR   PDBsum; 3IFC; -.
DR   PDBsum; 4HE0; -.
DR   PDBsum; 4HE1; -.
DR   PDBsum; 4HE2; -.
DR   ProteinModelPortal; O00757; -.
DR   SMR; O00757; 9-337.
DR   BioGrid; 114317; 3.
DR   IntAct; O00757; 20.
DR   MINT; MINT-1374932; -.
DR   STRING; 9606.ENSP00000364486; -.
DR   BindingDB; O00757; -.
DR   DEPOD; O00757; -.
DR   PhosphoSite; O00757; -.
DR   BioMuta; FBP2; -.
DR   MaxQB; O00757; -.
DR   PaxDb; O00757; -.
DR   PRIDE; O00757; -.
DR   DNASU; 8789; -.
DR   Ensembl; ENST00000375337; ENSP00000364486; ENSG00000130957.
DR   GeneID; 8789; -.
DR   KEGG; hsa:8789; -.
DR   UCSC; uc004auv.3; human.
DR   CTD; 8789; -.
DR   GeneCards; GC09M097321; -.
DR   HGNC; HGNC:3607; FBP2.
DR   HPA; HPA012513; -.
DR   MIM; 603027; gene.
DR   neXtProt; NX_O00757; -.
DR   PharmGKB; PA28019; -.
DR   eggNOG; COG0158; -.
DR   GeneTree; ENSGT00390000015513; -.
DR   HOGENOM; HOG000191265; -.
DR   HOVERGEN; HBG005627; -.
DR   InParanoid; O00757; -.
DR   KO; K03841; -.
DR   OMA; AGLAHMF; -.
DR   OrthoDB; EOG7GJ6D9; -.
DR   PhylomeDB; O00757; -.
DR   TreeFam; TF314824; -.
DR   BioCyc; MetaCyc:HS05462-MONOMER; -.
DR   Reactome; REACT_1520; Gluconeogenesis.
DR   SABIO-RK; O00757; -.
DR   UniPathway; UPA00138; -.
DR   EvolutionaryTrace; O00757; -.
DR   GenomeRNAi; 8789; -.
DR   NextBio; 32964; -.
DR   PRO; PR:O00757; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; O00757; -.
DR   CleanEx; HS_FBP2; -.
DR   Genevisible; O00757; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0030018; C:Z disc; IEA:UniProtKB-SubCell.
DR   GO; GO:0042132; F:fructose 1,6-bisphosphate 1-phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:Reactome.
DR   GO; GO:0006000; P:fructose metabolic process; TAS:ProtInc.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0006006; P:glucose metabolic process; TAS:Reactome.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   HAMAP; MF_01855; FBPase_class1; 1.
DR   InterPro; IPR000146; FBPase_class-1/SBPase.
DR   InterPro; IPR028343; FBPtase.
DR   InterPro; IPR020548; Fructose_bisphosphatase_AS.
DR   PANTHER; PTHR11556; PTHR11556; 1.
DR   Pfam; PF00316; FBPase; 1.
DR   PIRSF; PIRSF500210; FBPtase; 1.
DR   PIRSF; PIRSF000904; FBPtase_SBPase; 1.
DR   PRINTS; PR00115; F16BPHPHTASE.
DR   PROSITE; PS00124; FBPASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Calcium; Carbohydrate metabolism;
KW   Cell junction; Complete proteome; Cytoplasm; Gluconeogenesis;
KW   Hydrolase; Magnesium; Metal-binding; Nucleus; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1    339       Fructose-1,6-bisphosphatase isozyme 2.
FT                                /FTId=PRO_0000200504.
FT   NP_BIND      28     32       AMP. {ECO:0000269|PubMed:22120740}.
FT   NP_BIND     113    114       AMP. {ECO:0000269|PubMed:22120740}.
FT   REGION        3     10       Important for interaction with ALDOA.
FT   REGION      213    216       Substrate binding.
FT   REGION      245    249       Substrate binding.
FT   MOTIF       204    208       Nuclear localization signal.
FT                                {ECO:0000269|PubMed:19626708}.
FT   METAL        69     69       Magnesium 1.
FT   METAL        98     98       Magnesium 1.
FT   METAL        98     98       Magnesium 2.
FT   METAL       119    119       Magnesium 2.
FT   METAL       119    119       Magnesium 3.
FT   METAL       121    121       Magnesium 2; via carbonyl oxygen.
FT   METAL       122    122       Magnesium 3.
FT   METAL       281    281       Magnesium 3.
FT   BINDING      18     18       AMP; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:22120740}.
FT   BINDING     122    122       Substrate.
FT   BINDING     141    141       AMP. {ECO:0000269|PubMed:22120740}.
FT   BINDING     265    265       Substrate.
FT   BINDING     275    275       Substrate.
FT   SITE         33     33       Important for the conversion from active
FT                                R-state to inactive T-state in the
FT                                presence of AMP.
FT   VARIANT      86     86       V -> L (in dbSNP:rs573212).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:9678974}.
FT                                /FTId=VAR_024448.
FT   MUTAGEN       1     10       Missing: Greatly reduces sensitivity to
FT                                inhibition by AMP and Ca(2+) and
FT                                activation by Mg(2+). Decreases binding
FT                                to ALDOA. {ECO:0000269|PubMed:18214967}.
FT   MUTAGEN       1      7       Missing: Greatly reduces sensitivity to
FT                                inhibition by AMP and Ca(2+) and
FT                                activation by Mg(2+). Decreases binding
FT                                to ALDOA.
FT   MUTAGEN       1      6       Missing: Reduces sensitivity to
FT                                inhibition by AMP and Ca(2+) and
FT                                activation by Mg(2+). Decreases binding
FT                                to ALDOA.
FT   MUTAGEN       1      5       Missing: Reduces sensitivity to
FT                                inhibition by AMP and Ca(2+) and
FT                                activation by Mg(2+). Decreases binding
FT                                to ALDOA.
FT   MUTAGEN       1      4       Missing: Slightly reduces sensitivity to
FT                                inhibition by AMP and Ca(2+) and
FT                                activation by Mg(2+). Decreases binding
FT                                to ALDOA.
FT   MUTAGEN       1      3       Missing: No effect on kinetic properties
FT                                but decreases binding to ALDOA.
FT   MUTAGEN       1      2       Missing: No effect on kinetic properties
FT                                and interaction with ALDOA.
FT   MUTAGEN       1      1       Missing: No effect on kinetic properties
FT                                and interaction with ALDOA.
FT   MUTAGEN      21     21       K->E: Reduces sensitivity to AMP; when
FT                                associated with M-178 and C-180.
FT                                {ECO:0000269|PubMed:16213487}.
FT   MUTAGEN      33     33       Q->R: Causes conformational change of N-
FT                                terminal residues and decreased
FT                                sensitivity towards AMP with lack of
FT                                conversion to the inactive T-state in the
FT                                presence of AMP.
FT   MUTAGEN      70     70       E->Q: Greatly reduces affinity towards
FT                                Ca(2+) and slightly reduces affinity
FT                                towards Mg(2+).
FT                                {ECO:0000269|PubMed:17350621}.
FT   MUTAGEN     178    178       T->M: Reduces sensitivity to AMP; when
FT                                associated with E-21 and C-180.
FT                                {ECO:0000269|PubMed:16213487}.
FT   MUTAGEN     180    180       Q->C: Reduces sensitivity to AMP; when
FT                                associated with E-21 and M-178.
FT                                {ECO:0000269|PubMed:16213487}.
FT   MUTAGEN     204    208       KKKGK->AAAGA,EEEGE: Almost completely
FT                                abolishes nuclear localization.
FT                                {ECO:0000269|PubMed:19626708}.
FT   MUTAGEN     204    204       K->E: Minor reduction in nuclear
FT                                localization.
FT   MUTAGEN     205    205       K->E: Minor reduction in nuclear
FT                                localization.
FT   MUTAGEN     206    206       K->E: Greatly reduces nuclear
FT                                lozalization.
FT   MUTAGEN     208    208       K->E: Significantly reduces nuclear
FT                                localization.
FT   HELIX        14     24       {ECO:0000244|PDB:4HE2}.
FT   HELIX        30     50       {ECO:0000244|PDB:4HE2}.
FT   TURN         51     54       {ECO:0000244|PDB:4HE2}.
FT   TURN         59     61       {ECO:0000244|PDB:3IFA}.
FT   STRAND       70     72       {ECO:0000244|PDB:4HE0}.
FT   HELIX        74     87       {ECO:0000244|PDB:4HE2}.
FT   TURN         88     90       {ECO:0000244|PDB:4HE2}.
FT   STRAND       92     97       {ECO:0000244|PDB:4HE2}.
FT   HELIX       108    110       {ECO:0000244|PDB:4HE2}.
FT   STRAND      111    122       {ECO:0000244|PDB:4HE2}.
FT   HELIX       124    126       {ECO:0000244|PDB:4HE2}.
FT   TURN        127    130       {ECO:0000244|PDB:4HE2}.
FT   STRAND      133    141       {ECO:0000244|PDB:4HE2}.
FT   HELIX       150    153       {ECO:0000244|PDB:4HE2}.
FT   HELIX       157    159       {ECO:0000244|PDB:4HE2}.
FT   STRAND      161    180       {ECO:0000244|PDB:4HE2}.
FT   STRAND      182    188       {ECO:0000244|PDB:4HE2}.
FT   TURN        189    192       {ECO:0000244|PDB:4HE2}.
FT   STRAND      193    201       {ECO:0000244|PDB:4HE2}.
FT   STRAND      208    211       {ECO:0000244|PDB:4HE2}.
FT   HELIX       214    219       {ECO:0000244|PDB:4HE2}.
FT   HELIX       222    232       {ECO:0000244|PDB:4HE2}.
FT   STRAND      235    237       {ECO:0000244|PDB:4HE2}.
FT   HELIX       249    259       {ECO:0000244|PDB:4HE2}.
FT   STRAND      262    265       {ECO:0000244|PDB:4HE2}.
FT   STRAND      269    271       {ECO:0000244|PDB:4HE0}.
FT   STRAND      275    277       {ECO:0000244|PDB:4HE2}.
FT   TURN        278    281       {ECO:0000244|PDB:4HE2}.
FT   HELIX       282    291       {ECO:0000244|PDB:4HE2}.
FT   STRAND      295    297       {ECO:0000244|PDB:4HE2}.
FT   STRAND      299    302       {ECO:0000244|PDB:4HE2}.
FT   HELIX       303    305       {ECO:0000244|PDB:4HE2}.
FT   STRAND      317    321       {ECO:0000244|PDB:4HE2}.
FT   HELIX       322    335       {ECO:0000244|PDB:4HE2}.
SQ   SEQUENCE   339 AA;  36743 MW;  196B06D744710BC4 CRC64;
     MTDRSPFETD MLTLTRYVME KGRQAKGTGE LTQLLNSMLT AIKAISSAVR KAGLAHLYGI
     AGSVNVTGDE VKKLDVLSNS LVINMVQSSY STCVLVSEEN KDAIITAKEK RGKYVVCFDP
     LDGSSNIDCL ASIGTIFAIY RKTSEDEPSE KDALQCGRNI VAAGYALYGS ATLVALSTGQ
     GVDLFMLDPA LGEFVLVEKD VKIKKKGKIY SLNEGYAKYF DAATTEYVQK KKFPEDGSAP
     YGARYVGSMV ADVHRTLVYG GIFLYPANQK SPKGKLRLLY ECNPVAYIIE QAGGLATTGT
     QPVLDVKPEA IHQRVPLILG SPEDVQEYLT CVQKNQAGS
//
